New Launch1 Oct 2025, 03:06 pm
Lupin Launches Rivaroxaban for Oral Suspension in the United States
AI Summary
Global pharma major Lupin Limited has announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States. The product is bioequivalent to Xarelto® for Oral Suspension, 1 mg/mL of Janssen Pharmaceuticals, Inc. Rivaroxaban for Oral Suspension is indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients from birth to less than 18 years after at least 5 days of initial parenteral anticoagulant treatment. It is also indicated for thromboprophylaxis in pediatric patients 2 years and older with congenital heart disease after the Fontan procedure. The product had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT July 2025).
Key Highlights
- Lupin Limited launches Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States.
- The product is bioequivalent to Xarelto® for Oral Suspension, 1 mg/mL of Janssen Pharmaceuticals, Inc.
- Indicated for the treatment of venous thromboembolism (VTE) and reduction in the risk of recurrent VTE in pediatric patients.
- Also indicated for thromboprophylaxis in pediatric patients with congenital heart disease after the Fontan procedure.
- Had estimated annual sales of USD 11 million in the U.S. (IQVIA MAT July 2025).